Zhichao Wu

Zhichao Wu

Auto-generated profile, based on publicly available information

Zhichao Wu

Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Ophthalmology
Verified
Journal Article
Closed access
AYAdeleh Yarmohammadi
Adeleh Yarmohammadi
LZLinda M. Zangwill
Linda M. Zangwill
ADAlberto Diniz-Filho
Alberto Diniz-Filho
LSLuke J. Saunders
Luke J. Saunders
MSMin Hee Suh
Min Hee Suh
RWRobert N Weinreb
Robert N Weinreb

1 June 2019 in Ophthalmology
Verified
Journal Article
Open access
RGRobyn Guymer
Robyn Guymer
ZWZhichao Wu
Zhichao Wu
LHLauren A.B. Hodgson
Lauren A.B. Hodgson
ECEmily Caruso
Emily Caruso
KBKate H. Brassington
Kate H. Brassington
CLChi Luu
Chi Luu
There is an urgent need for a more effective intervention to slow or prevent progression of age-related macular degeneration (AMD) from its early stages to vision-threatening late complications. Subthreshold nanosecond laser (SNL) treatment has shown promise in preclinical studies and a pilot study in intermediate AMD (iAMD) as a potential treatment. We aimed to evaluate the safety of SNL treatment in iAMD and its efficacy for slowing progression to late AMD. The Laser Intervention in Early Stages of Age-Related Macular Degeneration (LEAD) study is a 36-month, multicenter, randomized, sham-controlled trial. Two hundred ninety-two participants with bilateral large drusen and without OCT signs of atrophy. Participants were assigned randomly to receive Retinal Rejuvenation Therapy (2RT®; Ellex Pty Ltd, Adelaide, Australia) SNL or sham treatment to the study eye at 6-monthly intervals. The primary efficacy outcome was the time to development of late AMD defined by multimodal imaging (MMI). Safety was assessed by adverse events. Overall, progression to late AMD was not slowed significantly with SNL treatment compared with sham treatment (adjusted hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.33-1.14; P = 0.122). However, a post hoc analysis showed evidence of effect modification based on the coexistence of reticular pseudodrusen (RPD; adjusted interaction P = 0.002), where progression was slowed for the 222 participants (76.0%) without coexistent RPD at baseline (adjusted HR, 0.23; 95% CI, 0.09-0.59; P = 0.002), whereas an increased progression rate (adjusted HR, 2.56; 95% CI, 0.80-8.18; P = 0.112) was observed for the 70 participants (24.0%) with RPD with SNL treatment. Differences between the groups in serious adverse events were not significant. In participants with iAMD without MMI-detected signs of late AMD, no significant difference in the overall progression rate to late AMD between those receiving SNL and sham treatment were observed. However, SNL treatment may have a role in slowing progression for those without coexistent RPD and may be inappropriate in those with RPD, warranting caution when considering treatment in clinical phenotypes with RPD. Our findings provide compelling evidence for further trials of the 2RT® laser, but they should not be extrapolated to other short-pulse lasers.

1 June 2017 in Ophthalmology
Verified
Journal Article
Closed access
ZWZhichao Wu
Zhichao Wu
LSLuke J. Saunders
Luke J. Saunders
FDFábio B. Daga
Fábio B. Daga
ADAlberto Diniz-Filho
Alberto Diniz-Filho
FMFelipe A. Medeiros
Felipe A. Medeiros

1 April 2015 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
ZWZhichao Wu
Zhichao Wu
LALauren N. Ayton
Lauren N. Ayton
CLChi Luu
Chi Luu
RGRobyn Guymer
Robyn Guymer
The hallmark clinical signs of age-related macular degeneration (AMD) in its early stages are the presence of drusen and pigmentary change in the macula, which can be present for many years prior to the development of vision-threatening complications. Significant progress has been made in understanding the pathogenic pathways involved in AMD and, as such, novel intervention strategies in the early stages of AMD are currently being developed or trialed.

1 June 2020 in Ophthalmology Retina
Verified
Journal Article
Closed access
ZWZhichao Wu
Zhichao Wu
CLChi D. Luu
Chi D. Luu
LHLauren A.B. Hodgson
Lauren A.B. Hodgson
ECEmily Caruso
Emily Caruso
NTNicole Tindill
Nicole Tindill
RGRobyn H. Guymer
Robyn H. Guymer

1 May 2020 in Ophthalmology
Verified
Journal Article
Closed access
CNCallum Narita
Callum Narita
ZWZhichao Wu
Zhichao Wu
PRPhilip J. Rosenfeld
Philip J. Rosenfeld
JYJin Yang
Jin Yang
CLCancan Lyu
Cancan Lyu
RGRobyn Guymer
Robyn Guymer